Gene · 6421
NIH grants1,450
NIH grants whose papers are about the gene, through NIH's grant-paper links.
681 to 700 of 1,450
Download this page as JSON| Grant | Title | SFPQ papers | Newest fiscal year |
|---|---|---|---|
| U54CA193461 | Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies | 1 | 2020 |
| U54NS091046 | Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells | 1 | 2020 |
| ZIAHD008964 | Regulation of retrograde cargo transport in axons | 1 | 2020 |
| ZIAHL004236 | Alternative Splicing of Nonmuscle Myosin Heavy Chains | 1 | 2020 |
| R01GM052872 | Regulation of RNA metabolism and cell growth control by SR protein kinases | 4 | 2019 |
| R01AI026765 | Impact of host protein dynamics on picornavirus RNA 5’ noncoding region functions | 3 | 2019 |
| R01GM049662 | The Regulation of Neuronal Exon Splicing | 3 | 2019 |
| I01BX002709 | SRSF3 Loss and Hepatocellular Carcinoma | 2 | 2019 |
| P50AG025688 | Emory Alzheimer's Disease Center | 2 | 2019 |
| P50GM115279 | Center for Precision Medicine in Leukemia (CPML) | 2 | 2019 |
| R00GM112877 | Understanding Epstein Barr virus oncogenicity through non-coding RNA structure | 2 | 2019 |
| R01CA188286 | SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA | 2 | 2019 |
| R01DK104681 | Activating cystic fibrosis transmembrane conductance regulator: the therapeutic potential of RNA directed gene activation | 2 | 2019 |
| R01GM056322 | Structural Study of GTPase Regulators and Effectors | 2 | 2019 |
| S10OD026929 | Illumina NovaSeq 6000 Sequencing System | 2 | 2019 |
| F30NS100595 | Single-molecule resolution of RNA editing of mRNAs: visualizing GRIA2 editing in situ in ALS | 1 | 2019 |
| I01RX002133 | ER Stress-induced Neurodegeneration as Therapeutic Targets for ALS | 1 | 2019 |
| K01NS110449 | Selectivity for Kinesin-driven Transport of Axonal RNA Granules | 1 | 2019 |
| K08CA188073 | Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma | 1 | 2019 |
| P01CA077852 | Molecular Determinants of Cancer Therapeutic Response | 1 | 2019 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6421/grants?page=35